Special Issue Archive

Latest Special Issue

Clinical Trials to Clinical Practice

Clinical Trials to Clinical Practice: GI Cancer Edition

OPDIVO® (nivolumab) in Combination with Chemotherapy as First-Line Therapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma as well as Unresectable Advanced or Metastatic Esophageal Squamous-Cell Carcinoma: Results from Checkmate 649 and Checkmate 648

Read more

Special Issues Archive

Clinical Trials to Clinical Practice: GI Cancer Edition

View Issue

Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

View Issue

2023 Oncology Guide to Patient Support Services

View Issue

2022 Year in Review: Multiple Myeloma

View Issue

2022 Year in Review: Cholangiocarcinoma

View Issue

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

View Issue

Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

View Issue

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

View Issue

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

View Issue

2022 Midyear Review: Non–Small-Cell Lung Cancer

View Issue

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

View Issue

ASK THE EXPERT: First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

View Issue